Pfizer Inc.'s COVID-19 treatment Paxlovid (nirmatrelvir/ritonavir) failed to show a benefit in a Phase II/III trial for post-exposure prophylactic (PEP) use, but the company is stressing that it does not impact its use as a treatment for people already infected with COVID-19 who are at high risk of hospitalization.
A fuller view of the long-term opportunity will come from the company’s first quarter sales and earnings report on 3...






